Related Experiment Videos
[Prevention of preeclampsia]
Dominique Desvaux1, Bassam Haddad
1Département de pathologie et service de néphrologie, AP-HP, Hôpital Henri Mondor, Créteil. dominique.desvaux@hmn.ap-hop-paris.fr
Presse Medicale (Paris, France : 1983)
|October 25, 2003
Summary
Low-dose aspirin is a safe and effective preventive treatment for preeclampsia, reducing risk by 15%. This intervention is recommended for high-risk pregnancies, particularly those with a history of preeclampsia.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Pharmacology
Context:
- Preeclampsia poses significant risks for maternal and perinatal health, including abruptio placentae, HELLP syndrome, eclampsia, and fetal demise.
- Effective prevention strategies are crucial for improving pregnancy outcomes and reducing maternal mortality.
- Identifying women who will benefit most from preventive measures is essential for targeted interventions.
Purpose:
- To review the current evidence on the prevention of preeclampsia.
- To evaluate the efficacy and safety of low-dose aspirin as a preventive treatment.
- To compare aspirin with other potential preventive therapies.
Summary:
- Low-dose aspirin is the most studied preventive treatment for preeclampsia, demonstrating safety in pregnant women across various risk groups.
- Studies indicate that low-dose aspirin use is associated with a 15% reduction in preeclampsia risk.
- Other preventive treatments like calcium have not shown consistent efficacy, while others like antioxidants and low molecular weight heparin require further confirmation.
Impact:
- The findings support the current clinical practice of using low-dose aspirin for preeclampsia prevention, especially in high-risk individuals.
- This evidence guides the selection of patients who are most likely to benefit from aspirin therapy.
- Further research may be needed to confirm the efficacy of alternative preventive treatments.